By Chris Wack


BeiGene shares were up 7% to $139.39 after the company said the European Commission has approved tislelizumab as a treatment for non-small cell lung cancer across multiple tumor types.

The approved indications for tislelizumab are, in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of adult patients with squamous non-small cell lung cancer. It also can be used as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer after prior platinum-based therapy.

BeiGene plans to combine the non-small cell lung cancer indications with the second-line indication under the brand name Tevimbra, which will launch in the first EU countries later in 2024. Tevimbra is approved in the U.S. and EU after prior chemotherapy.


Write to Chris Wack at chris.wack@wsj.com


(END) Dow Jones Newswires

04-23-24 1058ET